Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Inception Sciences
Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.
From Inception, Tempest Plans To Kick Up IO Storm
Emerging Company Profile: Spinning out of Versant Ventures’ Inception Sciences, San-Francisco-based development-stage biotech Tempest Therapeutics Inc. completes $70m Series B round to advance small molecules that modulate anti-tumor immunity pathways.
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
ARCH invests $150m in the Scangos-led Vir Biotechnology; Flagship recruits ex-Novartis executive Epstein; Versant closes a new $400m fund; and $601.1m in 11 other recent VC funding rounds.
Here To Stay: Inception Sciences Shows Why Build-To-Buy Works
Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Inception 1 (partnered with Shire)
- Inception 3 (partnered with Roche)
- Inception 4 (partnered with Bayer)
- Inception IBD
- Inception 5 (partnered with Roche)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.